Acute postoperative pain (APOP) is a major public health problem, affecting nearly 10 million patients in France each year. Effective analgesic therapy in the first postoperative week is a key factor in reducing early postoperative morbidity and mortality. Poorly controlled APOP is a major risk factor for chronic postoperative pain. In France today, more and more patients undergo surgical procedures as outpatients. The challenge is to manage postoperative pain in the homes of patients who have undergone increasingly complex surgical procedures, either after outpatient surgery or after a prompt return home as part of an Enhanced Recovery After Surgery (ERAS) protocol. In outpatient surgery, postoperative pain management requires new strategies and/or organizational approaches to ensure high-quality pain management from the very start. The principle of analgesia for acute postoperative pain recommends: i) routine, fixed-schedule maintenance therapy; and ii) rescue therapy if maintenance therapy is insufficient, based on pain titration, using mild or strong oral opioids. Postoperative pain is the primary focus of postoperative care but the goal is also to improve postoperative recovery and enhance the patient's overall care. To date, there are no medical telemonitoring devices to support the patient in properly taking their analgesics based on multiple-daily assessments of the efficacy and tolerability of the analgesic treatment, enabling systematic postoperative screening for early and late warning signs of the risk of chronic pain. The Thess Monitoring device, which implements the ANTALGEEK® protocol, (TMA) was developed to optimize the efficiency of outpatient management of acute postoperative pain. It improves patients' adherence to maintenance treatment with adaptive, personalized control of analgesia through better use of opioid rescue therapy, and the reduction of adverse effects associated with improper opioid use (under- or over-dosing). The aim is to ensure optimal pain resolution and improve early and late postoperative recovery during the first postoperative week. The TMA system enables remote monitoring of the efficacy and tolerability of analgesic treatment, as well as early and late warning signs of the risk of chronic pain. By measuring pain scores daily during the first postoperative week, it identifies patients with a suboptimal pain trajectory who are at high risk of developing persistent pain beyond the third month. It also assesses warning signs of the risk of chronic pain (neuropathic pain, persistent opioid use) at intervals following the procedure (Day 8, Month 1, Month 2, Month 3). Improving the patient care pathway via the TMA system should make it possible to better coordinate postoperative follow-up between hospital-based and community-based care.
The problem of acute postoperative pain (APOP) is a major public health problem, affecting nearly 10 million patients in France each year and potentially leading to numerous complications when inadequately managed. In the postoperative period, the implementation of effective analgesic therapy is a key factor in reducing early postoperative morbidity and mortality. Furthermore, poorly controlled PPS is one of the major risk factors for the development of chronic postoperative pain (CPOP). Optimizing analgesic medication to prevent an abnormal pain trajectory during the first postoperative week is a key strategy for preventing chronic postoperative pain. Today, within the French healthcare system, an increasing number of patients undergo surgical procedures performed on an outpatient basis. The big challenge is to manage postoperative pain in the homes of patients who have undergone increasingly complex surgical procedures, either following outpatient surgery or after an early return home as part of an Enhanced Recovery After Surgery (ERAS) protocol. In outpatient surgery, improving postoperative pain management requires the implementation of new strategies and/or organizational approaches to ensure a high-quality pain management pathway from the very beginning. The principle of analgesia for acute postoperative pain recommends a combination of: i) routine, fixed-schedule maintenance therapy; and ii) rescue therapy-if maintenance therapy is insufficient-based on the principle of pain titration, using oral opioids (mild or strong). While postoperative pain remains the primary focus of postoperative care, the goal is also to improve postoperative recovery more broadly and thereby enhance the patient's overall care. The assessment of postoperative recovery in outpatient surgery patients using a medical telemonitoring device is associated with a reduction in discomfort caused by various postoperative symptoms, including postoperative pain. However, to date, there is no medical telemonitoring device that both supports the patient in properly taking their analgesics based on multiple-daily assessments of the efficacy and tolerability of the analgesic treatment, and enables systematic postoperative screening for early and late warning signs of the risk of chronic pain. To this end, the Thess Monitoring medical telemonitoring device (which implements the ANTALGEEK® protocol) (TMA) was developed. It is a tool for continuous therapeutic support and postoperative telemonitoring designed to optimize the efficiency of outpatient management of acute postoperative pain in patients by improving adherence to maintenance therapy, adaptive and personalized control of analgesia through better use of opioid rescue therapy, and the reduction of adverse effects associated with improper opioid use (under- or over-dosing), with the goal of ensuring optimal pain resolution and improved early and late postoperative recovery during the first postoperative week (Baseline-Day 7). To achieve this, the TMA system enables remote monitoring of the efficacy and tolerability of analgesic treatment, as well as early and late warning signs of the risk of chronic pain: identify, through daily measurement of pain scores during the first postoperative week, patients with a suboptimal pain trajectory who are at high risk of developing persistent postoperative pain beyond the third month; assess warning signs of the risk of chronic pain (neuropathic pain, persistent opioid use) at intervals following the procedure (Day 8, Month 1, Month 2, Month 3). Improving the patient care pathway through the TMA system should thus make it possible to better coordinate postoperative follow-up between hospital-based and community-based care. In this initial proof-of-concept study, the investigators aim to evaluate the performance and safety of the TMA medical device in the outpatient management of acute pain during the first postoperative week, as well as its impact on postoperative recovery and on reducing the risk of pain becoming chronic by the third postoperative month.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Enrollment
150
The Thess monitoring medical device (Thess Corp., Montpellier) uses the remote ANTALGEEK® telemonitoring protocol to manage pain in outpatients who have had surgery causing moderate-to-severe pain. It digitalizes and optimizes acute postoperative pain management at home by improving adherence to maintenance therapy, with adaptive, tailored control of analgesia through better use of opioid rescue therapy to reduce the adverse effects of opioid misuse and ensures optimal pain resolution and postoperative recovery during the first week. The ANTALGEEK decision-making algorithm and a medical telemonitoring protocol help patients follow their pain medication regimen, monitoring them in postoperative Week 1, based on the preoperative prescription, data on the patient's adherence to treatment, its efficacy and tolerability.
Nimes University Hospital
Nîmes, Gard, France
RECRUITINGPerformance of the TMA® medical device (TMA group) according to the QoR-15 questionnaire score in the experimental group
The QoR-15 (quality of recovery) questionnaire comprises 15 items assessing different aspects of a patient's recovery : symptoms, functional status, and emotional well-being. The 15 items are grouped into five domains: Physical Comfort (symptoms like nausea, vomiting, and general discomfort), Emotional State (feelings such as anxiety, depression, or general well-being), Physical Independence (the patient's ability to look after themselves, such as mobility and self-care), Psychological Support (feelings of support and reassurance) Pain (the level of pain experienced by the patient). Each item in the QoR-15 is scored on an 11-point numerical scale ranging from 0 (none of the time/worst outcome) to 10 (all of the time/best outcome). The sum of the scores for each of the 15 items results in a score ranging from 0 (very poor recovery) to 150 (excellent quality of recovery). Excellent: QoR-15 score \> 135, Good: QoR-15 score between 122 and 135 (inclusive), Moderate: QoR-15 score between 90
Time frame: Day 2
Performance of the TMA® medical device (TMA group) according to the QoR-15 questionnaire score in the standard care (control) group.
The QoR-15 (quality of recovery) questionnaire comprises 15 items assessing different aspects of a patient's recovery : symptoms, functional status, and emotional well-being. The 15 items are grouped into five domains: Physical Comfort (symptoms like nausea, vomiting, and general discomfort), Emotional State (feelings such as anxiety, depression, or general well-being), Physical Independence (the patient's ability to look after themselves, such as mobility and self-care), Psychological Support (feelings of support and reassurance) Pain (the level of pain experienced by the patient). Each item in the QoR-15 is scored on an 11-point numerical scale ranging from 0 (none of the time/worst outcome) to 10 (all of the time/best outcome). The sum of the scores for each of the 15 items results in a score ranging from 0 (very poor recovery) to 150 (excellent quality of recovery). Excellent: QoR-15 score \> 135, Good: QoR-15 score between 122 and 135 (inclusive), Moderate: QoR-15 score between 90
Time frame: Day 2
Quality of postoperative recovery (QoR15) during the early and late phases of recovery in the experimental group
The QoR-15 (quality of recovery) questionnaire comprises 15 items assessing different aspects of a patient's recovery : symptoms, functional status, and emotional well-being. The 15 items are grouped into five domains: Physical Comfort (symptoms like nausea, vomiting, and general discomfort), Emotional State (feelings such as anxiety, depression, or general well-being), Physical Independence (the patient's ability to look after themselves, such as mobility and self-care), Psychological Support (feelings of support and reassurance) Pain (the level of pain experienced by the patient). Each item in the QoR-15 is scored on an 11-point numerical scale ranging from 0 (none of the time/worst outcome) to 10 (all of the time/best outcome). The sum of the scores for each of the 15 items results in a score ranging from 0 (very poor recovery) to 150 (excellent quality of recovery). Excellent: QoR-15 score \> 135, Good: QoR-15 score between 122 and 135 (inclusive), Moderate: QoR-15 score between 90
Time frame: Day 1, before the intervention
Quality of postoperative recovery (QoR15) during the early and late phases of recovery in the experimental group
The QoR-15 (quality of recovery) questionnaire comprises 15 items assessing different aspects of a patient's recovery : symptoms, functional status, and emotional well-being. The 15 items are grouped into five domains: Physical Comfort (symptoms like nausea, vomiting, and general discomfort), Emotional State (feelings such as anxiety, depression, or general well-being), Physical Independence (the patient's ability to look after themselves, such as mobility and self-care), Psychological Support (feelings of support and reassurance) Pain (the level of pain experienced by the patient). Each item in the QoR-15 is scored on an 11-point numerical scale ranging from 0 (none of the time/worst outcome) to 10 (all of the time/best outcome). The sum of the scores for each of the 15 items results in a score ranging from 0 (very poor recovery) to 150 (excellent quality of recovery). Excellent: QoR-15 score \> 135, Good: QoR-15 score between 122 and 135 (inclusive), Moderate: QoR-15 score between 90
Time frame: Day 1, after the intervention
Quality of postoperative recovery (QoR15) during the early and late phases of recovery in the experimental group
The QoR-15 (quality of recovery) questionnaire comprises 15 items assessing different aspects of a patient's recovery : symptoms, functional status, and emotional well-being. The 15 items are grouped into five domains: Physical Comfort (symptoms like nausea, vomiting, and general discomfort), Emotional State (feelings such as anxiety, depression, or general well-being), Physical Independence (the patient's ability to look after themselves, such as mobility and self-care), Psychological Support (feelings of support and reassurance) Pain (the level of pain experienced by the patient). Each item in the QoR-15 is scored on an 11-point numerical scale ranging from 0 (none of the time/worst outcome) to 10 (all of the time/best outcome). The sum of the scores for each of the 15 items results in a score ranging from 0 (very poor recovery) to 150 (excellent quality of recovery). Excellent: QoR-15 score \> 135, Good: QoR-15 score between 122 and 135 (inclusive), Moderate: QoR-15 score between 90
Time frame: Day 7
Quality of postoperative recovery (QoR15) during the early and late phases of recovery in the standard care (control) group
The QoR-15 (quality of recovery) questionnaire comprises 15 items assessing different aspects of a patient's recovery : symptoms, functional status, and emotional well-being. The 15 items are grouped into five domains: Physical Comfort (symptoms like nausea, vomiting, and general discomfort), Emotional State (feelings such as anxiety, depression, or general well-being), Physical Independence (the patient's ability to look after themselves, such as mobility and self-care), Psychological Support (feelings of support and reassurance) Pain (the level of pain experienced by the patient). Each item in the QoR-15 is scored on an 11-point numerical scale ranging from 0 (none of the time/worst outcome) to 10 (all of the time/best outcome). The sum of the scores for each of the 15 items results in a score ranging from 0 (very poor recovery) to 150 (excellent quality of recovery). Excellent: QoR-15 score \> 135, Good: QoR-15 score between 122 and 135 (inclusive), Moderate: QoR-15 score between 90
Time frame: Day 1, before the intervention
Quality of postoperative recovery (QoR15) during the early and late phases of recovery in the standard care (control) group
The QoR-15 (quality of recovery) questionnaire comprises 15 items assessing different aspects of a patient's recovery : symptoms, functional status, and emotional well-being. The 15 items are grouped into five domains: Physical Comfort (symptoms like nausea, vomiting, and general discomfort), Emotional State (feelings such as anxiety, depression, or general well-being), Physical Independence (the patient's ability to look after themselves, such as mobility and self-care), Psychological Support (feelings of support and reassurance) Pain (the level of pain experienced by the patient). Each item in the QoR-15 is scored on an 11-point numerical scale ranging from 0 (none of the time/worst outcome) to 10 (all of the time/best outcome). The sum of the scores for each of the 15 items results in a score ranging from 0 (very poor recovery) to 150 (excellent quality of recovery). Excellent: QoR-15 score \> 135, Good: QoR-15 score between 122 and 135 (inclusive), Moderate: QoR-15 score between 90
Time frame: Day 1, after the intervention
Quality of postoperative recovery (QoR15) during the early and late phases of recovery in the standard care (control) group
The QoR-15 (quality of recovery) questionnaire comprises 15 items assessing different aspects of a patient's recovery : symptoms, functional status, and emotional well-being. The 15 items are grouped into five domains: Physical Comfort (symptoms like nausea, vomiting, and general discomfort), Emotional State (feelings such as anxiety, depression, or general well-being), Physical Independence (the patient's ability to look after themselves, such as mobility and self-care), Psychological Support (feelings of support and reassurance) Pain (the level of pain experienced by the patient). Each item in the QoR-15 is scored on an 11-point numerical scale ranging from 0 (none of the time/worst outcome) to 10 (all of the time/best outcome). The sum of the scores for each of the 15 items results in a score ranging from 0 (very poor recovery) to 150 (excellent quality of recovery). Excellent: QoR-15 score \> 135, Good: QoR-15 score between 122 and 135 (inclusive), Moderate: QoR-15 score between 90
Time frame: Day 7
Pain progression in the experimental group
Average pain score over 24 hours according to the Visual Analog Scale (0 -10)
Time frame: Day 1
Pain progression in the experimental group
Average pain score over 24 hours according to the Visual Analog Scale (0 -10)
Time frame: Day 2
Pain progression in the experimental group
Average pain score over 24 hours according to the Visual Analog Scale (0 -10)
Time frame: Day 3
Pain progression in the experimental group
Average pain score over 24 hours according to the Visual Analog Scale (0 -10)
Time frame: Day 4
Pain progression in the experimental group
Average pain score over 24 hours according to the Visual Analog Scale (0 -10)
Time frame: Day 5
Pain progression in the experimental group
Average pain score over 24 hours according to the Visual Analog Scale (0 -10)
Time frame: Day 6
Pain progression in the experimental group
Average pain score over 24 hours according to the Visual Analog Scale (0 -10)
Time frame: Day 7
Pain progression in the experimental group
Average pain score over 24 hours according to the Visual Analog Scale (0 -10)
Time frame: Month 1
Pain progression in the experimental group
Average pain score over 24 hours according to the Visual Analog Scale (0 -10)
Time frame: Month 2
Pain progression in the experimental group
Average pain score over 24 hours according to the Visual Analog Scale (0 -10)
Time frame: Month 3
Pain progression in the in the standard care (control) group
Average pain score over 24 hours according to the Visual Analog Scale (0 -10)
Time frame: Day 1
Pain progression in the in the standard care (control) group
Average pain score over 24 hours according to the Visual Analog Scale (0 -10)
Time frame: Day 2
Pain progression in the in the standard care (control) group
Average pain score over 24 hours according to the Visual Analog Scale (0 -10)
Time frame: Day 3
Pain progression in the in the standard care (control) group
Average pain score over 24 hours according to the Visual Analog Scale (0 -10)
Time frame: Day 4
Pain progression in the in the standard care (control) group
Average pain score over 24 hours according to the Visual Analog Scale (0 -10)
Time frame: Day 5
Pain progression in the in the standard care (control) group
Average pain score over 24 hours according to the Visual Analog Scale (0 -10)
Time frame: Day 6
Pain progression in the in the standard care (control) group
Average pain score over 24 hours according to the Visual Analog Scale (0 -10)
Time frame: Day 7
Pain progression in the in the standard care (control) group
Average pain score over 24 hours according to the Visual Analog Scale (0 -10)
Time frame: Month 1
Pain progression in the in the standard care (control) group
Average pain score over 24 hours according to the Visual Analog Scale (0 -10)
Time frame: Month 2
Pain progression in the in the standard care (control) group
Average pain score over 24 hours according to the Visual Analog Scale (0 -10)
Time frame: Month 3
Rate of adherence to the standard pain management regimen (non-opioid analgesics) in the experimental group
Patient's declaration in the Thess Monitoring Application
Time frame: Baseline
Rate of adherence to the standard pain management regimen (non-opioid analgesics) in the standard care (control) group
Phone call from the patient
Time frame: Baseline
rate of adherence to the standard pain management regimen (non-opioid analgesics) in the in the standard care (control) group
Phone call from the patient
Time frame: Day 1
Rate of adherence to the standard pain management regimen (non-opioid analgesics) in the experimental group
Patient's declaration in the Thess Monitoring Application
Time frame: Day 2
Rate of adherence to the standard pain management regimen (non-opioid analgesics) in the standard care (control) group
Phone call from the patient
Time frame: Day 2
Rate of adherence to the standard pain management regimen (non-opioid analgesics) in the experimental group
Patient's declaration in the Thess Monitoring Application
Time frame: Day 3
Rate of adherence to the standard pain management regimen (non-opioid analgesics) in the standard care (control) group
Phone call from the patient
Time frame: Day 3
Rate of adherence to the standard pain management regimen (non-opioid analgesics) in the experimental group
Patient's declaration in the Thess Monitoring Application
Time frame: Day 4
Rate of adherence to the standard pain management regimen (non-opioid analgesics) in the standard care (control) group
Phone call from the patient
Time frame: Day 4
Rate of adherence to the standard pain management regimen (non-opioid analgesics) in the experimental group
Patient's declaration in the Thess Monitoring Application
Time frame: Day 5
Rate of adherence to the standard pain management regimen (non-opioid analgesics) in the standard care (control) group
Phone call from the patient
Time frame: Day 5
Rate of adherence to the standard pain management regimen (non-opioid analgesics) in the experimental group
Patient's declaration in the Thess Monitoring Application
Time frame: Day 6
Rate of adherence to the standard pain management regimen (non-opioid analgesics) in the standard care (control) group
Phone call from the patient
Time frame: Day 6
Rate of adherence to the standard pain management regimen (non-opioid analgesics) in the experimental group
Patient's declaration in the Thess Monitoring Application
Time frame: Day 7
Rate of adherence to the standard pain management regimen (non-opioid analgesics) in the standard care (control) group
Phone call from the patient
Time frame: Day 7
Incidence of adverse effects associated with opioid use in the experimental group
Adverse effects associated with opioid use will be recorded on the Thess Monitoring Application Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no
Time frame: Baseline
Incidence of adverse effects associated with opioid use in the standard care (control) group
Adverse effects associated with opioid use will be recorded via a phone call to the patient Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no
Time frame: Baseline
Incidence of adverse effects associated with opioid use in the experimental group
Adverse effects associated with opioid use will be recorded on the Thess Monitoring Application Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no
Time frame: Day 1
Incidence of adverse effects associated with opioid use in the standard care (control) group
Adverse effects associated with opioid use will be recorded via a phone call to the patient Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no
Time frame: Day 1
Incidence of adverse effects associated with opioid use in the experimental group
Adverse effects associated with opioid use will be recorded on the Thess Monitoring Application Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no
Time frame: Day 2
Incidence of adverse effects associated with opioid use in the standard care (control) group
Adverse effects associated with opioid use will be recorded via a phone call to the patient Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no
Time frame: Day 2
Incidence of adverse effects associated with opioid use in the experimental group
Adverse effects associated with opioid use will be recorded on the Thess Monitoring Application Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no
Time frame: Day 3
Incidence of adverse effects associated with opioid use in the standard care (control) group
Adverse effects associated with opioid use will be recorded via a phone call to the patient Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no
Time frame: Day 3
Incidence of adverse effects associated with opioid use in the experimental group
Adverse effects associated with opioid use will be recorded on the Thess Monitoring Application Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no
Time frame: Day 4
Incidence of adverse effects associated with opioid use in the standard care (control) group
Adverse effects associated with opioid use will be recorded via a phone call to the patient Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no
Time frame: Day 4
Incidence of adverse effects associated with opioid use in the experimental group
Adverse effects associated with opioid use will be recorded on the Thess Monitoring Application Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no
Time frame: Day 5
Incidence of adverse effects associated with opioid use in the standard care (control) group
Adverse effects associated with opioid use will be recorded via a phone call to the patient Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no
Time frame: Day 5
Incidence of adverse effects associated with opioid use in the experimental group
Adverse effects associated with opioid use will be recorded on the Thess Monitoring Application Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no
Time frame: Day 6
Incidence of adverse effects associated with opioid use in the standard care (control) group
Adverse effects associated with opioid use will be recorded via a phone call to the patient Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no
Time frame: Day 6
Incidence of adverse effects associated with opioid use in the experimental group
Adverse effects associated with opioid use will be recorded on the Thess Monitoring Application Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no
Time frame: Day 7
Incidence of adverse effects associated with opioid use in the standard care (control) group
Adverse effects associated with opioid use will be recorded via a phone call to the patient Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no
Time frame: Day 7
Adverse Events [Safety and Tolerability] in the experimental group
Qualitative assessment. Any adverse events of any cause related to treatment will be recorded in the electronic clinical registration form following a phone call to the patient.
Time frame: Day 7
Adverse Events [Safety and Tolerability]in the standard care (control) group
Qualitative assessment. Any adverse events of any cause related to treatment will be recorded in the electronic clinical registration form following a phone call to the patient.
Time frame: Day 7
Use of medication (including opioid medications and treatments outside the standard regimen) in the experimental group
Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection via the Tess Monitoring Application
Time frame: Day 1
Use of medication (including opioid medications and treatments outside the standard regimen) in the standard care (control) group
Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection on the electronic clinical registration form
Time frame: Day 1
Use of medication (including opioid medications and treatments outside the standard regimen) in the experimental group
Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection via the Tess Monitoring Application
Time frame: Day 2
Use of medication (including opioid medications and treatments outside the standard regimen) in the standard care (control) group
Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection on the electronic clinical monitoring form
Time frame: Day 2
Use of medication (including opioid medications and treatments outside the standard regimen) in the experimental group
Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection via the Tess Monitoring Application
Time frame: Day 3
Use of medication (including opioid medications and treatments outside the standard regimen) in the standard care (control) group
Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection on the electronic clinical registration form
Time frame: Day 3
Use of medication (including opioid medications and treatments outside the standard regimen) in the experimental group
Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection via the Tess Monitoring Application
Time frame: Day 4
Use of medication (including opioid medications and treatments outside the standard regimen) in the standard care (control) group
Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection on the electronic clinical registration form
Time frame: Day 4
Use of medication (including opioid medications and treatments outside the standard regimen) in the experimental group
Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection via the Tess Monitoring Application
Time frame: Day 5
Use of medication (including opioid medications and treatments outside the standard regimen) in the standard care (control) group
Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection on the electronic clinical registration form
Time frame: Day 5
Use of medication (including opioid medications and treatments outside the standard regimen) in the experimental group
Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection via the Tess Monitoring Application
Time frame: Day 6
Use of medication (including opioid medications and treatments outside the standard regimen) in the standard care (control) group
Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection on the electronic clinical registration form
Time frame: Day 6
Use of medication (including opioid medications and treatments outside the standard regimen) in the experimental group
Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection via the Tess Monitoring Application
Time frame: Day 7
Use of medication (including opioid medications and treatments outside the standard regimen) in the standard care (control) group
Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection on the electronic clinical monitoring form
Time frame: Day 7
Use of medication (including opioid medications and treatments outside the standard regimen) in the experimental group
Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection via the Tess Monitoring Application and a phone call to the patient
Time frame: Month 1
Use of medication (including opioid medications and treatments outside the standard regimen) in the standard care (control) group
Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection on the electronic clinical registration form and a phone call to the patient
Time frame: Month 1
Use of medication (including opioid medications and treatments outside the standard regimen) in the experimental group
Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection via the Tess Monitoring Application and a phone call to the patient
Time frame: Month 3
Use of medication (including opioid medications and treatments outside the standard regimen) in the standard care (control) group
Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection on the electronic clinical registration form and a phone call to the patient
Time frame: Month 3
Number of unplanned medical appointments and telephone contacts with healthcare professionals after discharge from hospital in the experimental group
Data collection via the Tess Monitoring Application
Time frame: Day 1
Number of unplanned medical appointments and telephone contacts with healthcare professionals after discharge from hospital in the standard care (control) group
Data collection on the electronic clinical registration form
Time frame: Day 1
Number of unplanned medical appointments and telephone contacts with healthcare professionals after discharge from hospital in the experimental group
Data collection via the Tess Monitoring Application
Time frame: Day 2
Number of unplanned medical appointments and telephone contacts with healthcare professionals after discharge from hospital in the standard care (control) group
Data collection on the electronic clinical registration form
Time frame: Day 2
Number of unplanned medical appointments and telephone contacts with healthcare professionals after discharge from hospital in the experimental group
Data collection via the Tess Monitoring Application
Time frame: Day 3
Number of unplanned medical appointments and telephone contacts with healthcare professionals after discharge from hospital in the standard care (control) group
Data collection on the electronic clinical registration form
Time frame: Day 3
Number of unplanned medical appointments and telephone contacts with healthcare professionals after discharge from hospital in the experimental group
Data collection via the Tess Monitoring Application
Time frame: Day 4
Number of unplanned medical appointments and telephone contacts with healthcare professionals after discharge from hospital in the standard care (control) group
Data collection on the electronic clinical registration form
Time frame: Day 4
Prescription issued outside of those prescribed upon hospital discharge in the experimental group
Quantitative
Time frame: Month 3
Prescription issued outside of those prescribed upon hospital discharge in the standard care(control) group
Quantitative
Time frame: Month 3
Number of days of sick leave prescribed in the experimental group
Quantitative
Time frame: Month 3
Number of days of sick leave prescribed in the standard care (control) group
Quantitative
Time frame: Month 3
Satisfaction questionnaire administered to the patient in the experimental group
Qualitative
Time frame: Day 3
Satisfaction questionnaire administered to the patient in the standard care (control) group
Qualitative
Time frame: Day 3
Satisfaction questionnaire administered to the anesthesiologist in the experimental group
Qualitative
Time frame: End of the inclusion period
Satisfaction questionnaire administered to the anesthesiologist in the standard care (control) group
Qualitative
Time frame: End of the inclusion period
System Usability Scale score during the follow-up call to patients in the experimental group
The System Usability Scale (SUS) score is a measure of the usability of an interactive system, derived from a questionnaire that includes ten items. Each item is presented as a positive statement, and users are asked to indicate their agreement or disagreement with it using a 5-point Likert scale. The score is recalculated based on the number of items answered correctly, with a score of 2.5 for each item. This scoring system allows the assessment of user satisfaction and the overall usability of the system.
Time frame: Day 30
System Usability Scale score from health providers to the experimental group
The System Usability Scale (SUS) score is a measure of the usability of an interactive system, derived from a questionnaire that includes ten items. Each item is presented as a positive statement, and users are asked to indicate their agreement or disagreement with it using a 5-point Likert scale. The score is recalculated based on the number of items answered correctly, with a score of 2.5 for each item. This scoring system allows the assessment of user satisfaction and the overall usability of the system.
Time frame: End of the inclusion period
System Usability Scale score during the follow-up call to patients in the standard care (control) group
The System Usability Scale (SUS) score is a measure of the usability of an interactive system, derived from a questionnaire that includes ten items. Each item is presented as a positive statement, and users are asked to indicate their agreement or disagreement with it using a 5-point Likert scale. The score is recalculated based on the number of items answered correctly, with a score of 2.5 for each item. This scoring system allows the assessment of user satisfaction and the overall usability of the system.
Time frame: Day 30
System Usability Scale score from health providers to the standard care (control) group
The System Usability Scale (SUS) score is a measure of the usability of an interactive system, derived from a questionnaire that includes ten items. Each item is presented as a positive statement, and users are asked to indicate their agreement or disagreement with it using a 5-point Likert scale. The score is recalculated based on the number of items answered correctly, with a score of 2.5 for each item. This scoring system allows the assessment of user satisfaction and the overall usability of the system.
Time frame: End of the inclusion period
DN2 questionnaire score in the experimental group
The DN2 questionnaire is a simplified version of the DN4 (omitting the clinical examination), developed in France in 2005 by Bouhassira and the French Neuropathic Pain Group. It consists of two questions assessing the presence or absence of seven symptoms suggestive of neuropathic pain : burning, painful cold, electric shocks, tingling, prickling, numbness, and itching. The cutoff for a positive DN2 result is set at 3 out of 7 points. A positive DN2 result does not establish a formal diagnosis of neuropathic pain, as a clinical examination remains essential.
Time frame: Post-operative Month 1
DN2 questionnaire score in the experimental group
The DN2 questionnaire is a simplified version of the DN4 (omitting the clinical examination), developed in France in 2005 by Bouhassira and the French Neuropathic Pain Group. It consists of two questions assessing the presence or absence of seven symptoms suggestive of neuropathic pain : burning, painful cold, electric shocks, tingling, prickling, numbness, and itching. The cutoff for a positive DN2 result is set at 3 out of 7 points. A positive DN2 result does not establish a formal diagnosis of neuropathic pain, as a clinical examination remains essential.
Time frame: Post-operative Month 2
DN2 questionnaire score in the experimental group
The DN2 questionnaire is a simplified version of the DN4 (omitting the clinical examination), developed in France in 2005 by Bouhassira and the French Neuropathic Pain Group. It consists of two questions assessing the presence or absence of seven symptoms suggestive of neuropathic pain : burning, painful cold, electric shocks, tingling, prickling, numbness, and itching. The cutoff for a positive DN2 result is set at 3 out of 7 points. A positive DN2 result does not establish a formal diagnosis of neuropathic pain, as a clinical examination remains essential.
Time frame: Post-operative Month 3
DN2 questionnaire score in the standard care (control) group
The DN2 questionnaire is a simplified version of the DN4 (omitting the clinical examination), developed in France in 2005 by Bouhassira and the French Neuropathic Pain Group. It consists of two questions assessing the presence or absence of seven symptoms suggestive of neuropathic pain : burning, painful cold, electric shocks, tingling, prickling, numbness, and itching. The cutoff for a positive DN2 result is set at 3 out of 7 points. A positive DN2 result does not establish a formal diagnosis of neuropathic pain, as a clinical examination remains essential.
Time frame: Post-operative Month 1
DN2 questionnaire score in the standard care (control) group
The DN2 questionnaire is a simplified version of the DN4 (omitting the clinical examination), developed in France in 2005 by Bouhassira and the French Neuropathic Pain Group. It consists of two questions assessing the presence or absence of seven symptoms suggestive of neuropathic pain : burning, painful cold, electric shocks, tingling, prickling, numbness, and itching. The cutoff for a positive DN2 result is set at 3 out of 7 points. A positive DN2 result does not establish a formal diagnosis of neuropathic pain, as a clinical examination remains essential.
Time frame: Post-operative Month 2
DN2 questionnaire score in the standard care (control) group
The DN2 questionnaire is a simplified version of the DN4 (omitting the clinical examination), developed in France in 2005 by Bouhassira and the French Neuropathic Pain Group. It consists of two questions assessing the presence or absence of seven symptoms suggestive of neuropathic pain : burning, painful cold, electric shocks, tingling, prickling, numbness, and itching. The cutoff for a positive DN2 result is set at 3 out of 7 points. A positive DN2 result does not establish a formal diagnosis of neuropathic pain, as a clinical examination remains essential.
Time frame: Post-operative Month 3
Rate of incidents, malfunctions, and organization deviations that occurred during implementation in the experimental group
Qualitative
Time frame: Month 3
Time spent connected to the Thess Monitoring device per patient in the experimental group
Quantitative, in minutes
Time frame: Month 3
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.